Role of CAR-T therapies in haematological malignancies

CAR-T therapy products offer personalized, long-term therapeutic benefits for haematological malignancies. However, complexity of these products post many safety challenges.

Download Now

Article Highlights

  • The evolution of CAR T-cell therapy
  • Advantages over conventional therapies
  • Autologous and allogenic CAR T-cell therapies
  • Key challenges, routine, and additional pharmacovigilance activities
  • Measures to minimize or mitigate the risks identified.

Role of CAR-T therapies in haematological malignancies

 

Download Now
Download this publication now!
test

    Please note that by submitting this form, you consent to your personal data being processed in alignment with our Privacy Policy. APCER is committed to ensuring the security and protection of your personal information. Your personal data will be processed for purpose of facilitating your request and may be used for sending you additional marketing and business development-related information about APCER Life Sciences, its affiliates and our services. You can withdraw your consent by writing to us at DPO@apcerls.com.